Yakira Capital Management Inc. reduced its position in Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 79.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,489 shares of the biopharmaceutical company's stock after selling 404,900 shares during the period. Yakira Capital Management Inc. owned about 0.12% of Chimerix worth $360,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of CMRX. Bender Robert & Associates acquired a new position in Chimerix during the fourth quarter worth about $37,000. Stoneridge Investment Partners LLC raised its position in shares of Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company's stock worth $154,000 after purchasing an additional 8,134 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in Chimerix in the 4th quarter valued at approximately $183,000. Palumbo Wealth Management LLC purchased a new stake in Chimerix in the 4th quarter valued at approximately $221,000. Finally, Valeo Financial Advisors LLC grew its holdings in Chimerix by 78.8% during the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock valued at $509,000 after buying an additional 64,420 shares during the last quarter. 45.42% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the stock. Wedbush reiterated a "neutral" rating and set a $8.55 price target (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. HC Wainwright reaffirmed a "neutral" rating and issued a $8.55 target price (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. StockNews.com assumed coverage on Chimerix in a research note on Tuesday. They set a "hold" rating on the stock. Finally, Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.
Read Our Latest Research Report on Chimerix
Chimerix Trading Down 0.1 %
Chimerix stock traded down $0.01 during midday trading on Friday, hitting $8.53. The stock had a trading volume of 955,705 shares, compared to its average volume of 2,199,896. The business has a fifty day moving average price of $6.86 and a 200 day moving average price of $3.68. Chimerix, Inc. has a 12 month low of $0.75 and a 12 month high of $8.55. The stock has a market cap of $799.68 million, a P/E ratio of -9.07 and a beta of -0.17.
Chimerix (NASDAQ:CMRX - Get Free Report) last posted its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.31 million. On average, equities analysts anticipate that Chimerix, Inc. will post -0.99 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, CEO Michael T. Andriole sold 7,370 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now owns 609,603 shares of the company's stock, valued at $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 20,760 shares of company stock worth $91,175. Insiders own 13.10% of the company's stock.
About Chimerix
(
Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Read More
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
